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Abstract: The envelope protein (Env) is the only surface protein of the human immunodeficiency virus
(HIV) and as such the exclusive target for protective antibody responses. Experimental evidences from
mouse models suggest a modulating property of Env to steer antibody class switching towards the less
effective antibody subclass IgG1 accompanied with strong TH2 helper responses. By simple physical
linkage we were able to imprint this bias, exemplified by a low IgG2a/IgG1 ratio of antigen-specific
antibodies, onto an unrelated antigen, namely the HIV capsid protein p24. Here, our results indicate
the glycan moiety of Env as the responsible immune modulating activity. Firstly, in Card9−/−
mice lacking specific C-Type lectin responsiveness, DNA immunization significantly increased the
IgG2a/IgG1 ratio for the Env-specific antibodies while the antibody response against the F-protein
of the respiratory syncytial virus (RSV) serving as control antigen remained unchanged. Secondly,
sequential shortening of the Env encoding sequence revealed the C2V3 domain as responsible for the
strong IgG1 responses and TH2 cytokine production. Removing all potential N-glycosylation sites
from the C2V3 domain by site-specific mutagenesis reversed the vaccine-induced immune response
towards a Th1-dominated T-cell response and a balanced IgG2a/IgG1 ratio. Accordingly, the stretch
of oligomannose glycans in the C2V3 domain of Env might mediate a specific uptake and/or signaling
modus in antigen presenting cells by involving interaction with an as yet unknown C-type lectin
receptor. Our results contribute to a deeper understanding of the impact of Env glycosylation on HIV
antigen-specific immune responses, which will further support HIV vaccine development.
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1. Introduction
Vaccines are among the most effective measures to prevent infectious diseases. The most common
correlate of protection for licensed vaccines is a strong antibody response [1]. Unfortunately, the
classical vaccination approaches using inactivated or live-attenuated viruses were either not successful
or not applicable due to safety concerns in the context of an HIV vaccine. However, a comparison
of the vaccine-induced immune responses from the large clinical HIV-1 vaccine trials suggests that
the quality of the humoral immune response may be critically important for protection rather than
merely its quantity. Particularly, the protection against HIV infection in the RV144 trial correlated with
Env-specific IgG3 antibodies and the ability to induce ADCC [2]. In contrast, the same monomeric
gp120 protein vaccine used in the Vax003 study induced higher overall antibody levels but could
not provide protection [2–5]. Here, the dominating subtype has been IgG1, which seemed to be less
potent in Fc-Receptor (FcR) mediated secondary functions as compared to IgG3 [6,7]. Based on their
affinity for FcRs, murine IgG2a seems to be the functional analog of human IgG3 [8,9] and is strongly
associated with antiviral Th1 immune responses in mice [10]. Intriguingly, mIgG2a has been shown to
be superior to mIgG1 with regard to protection from viral infections [11,12]. Interestingly, concurrent
immunization against HIV Env and Gag with either gene-based vaccines or virus-like particles resulted
in a balanced IgG2a/IgG1 antibody response to Gag, but the Env-specific response in the same animal
was strongly dominated by IgG1 [13]. The induction of IgG1 antibodies was also accompanied by
a strong Env-specific TH2 response, as indicated by IL-5 and IL-13 producing CD4++ T-cells. The
bias towards IgG1 antibody responses to HIV Env was in line with the results from several other
immunization/infection experiments [14–16]. Furthermore, differences in the T-helper cell response
induced by Gag and Env were also observed in human volunteers which have been vaccinated with
ALVAC-HIV, a canarypox vector encoding the HIV antigens [13]. Since both antigens were delivered
by the same vector and route, we hypothesize that this bias may be attributable to an intrinsic property
of HIV Env. The resulting antibody response might be insufficient to promote protection or viral
clearance by FcR-mediated effector functions and thus might also provide a kind of immune escape
for HIV. The differentiation of T-helper cell responses depends mainly on the interaction with the
antigen-presenting cell (APC), in particular with the affinity of the TCR to MHCII/peptide complex,
the expression of co-stimulatory molecules, and the cytokines produced by the APC [17,18]. The
latter depend very much on the engagement of different pattern-recognition-receptors (PRR) [19–21].
Furthermore, the glycosylation pattern of an antigen has also been implicated in immune modulation
by promoting certain antibody or T-cell responses [22–25]. Since, in contrast to Gag, HIV Env is heavily
glycosylated, binding of Env to certain C-type lectin receptors (CLR) on different APC populations
might influence T-cell priming and/or B-cell activation [26–29]. Some CLRs induce the activation
of tyrosine kinases, such as Syk, through classical immunoreceptor tyrosine-based activation motifs
(ITAMs) or hemITAMs. This leads to the assembly of a ternary protein complex consisting of the
caspase recruitment domain-containing protein 9 (CARD9), B-cell lymphoma/leukemia 10 (Bcl10),
and the mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT-1). In contrast,
other CLRs carry intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus they are
capable of dampening cellular responses.
In this study, we evaluated these structural properties of HIV Env as potential drivers of the biased
T-cell and/or antibody responses. We applied DNA vaccines encoding HIV Env or other viral surface
glycoproteins, namely the F-protein from the respiratory syncytial virus (RSV-F) or hemagglutinin
from influenza a virus (IAV-HA), to characterize the differential antibody and T-cell responses in
mice. Furthermore, we addressed whether TLR- or CLR-signaling is important for the IgG1 bias by
application of respective knock-out animals. Finally, we identified the glycosylation of HIV Env in the
C2V3 region as critical modulator of the antibody response toward the less efficient IgG1 subtype.
Viruses 2019, 11, 153 3 of 16
2. Materials and Methods
2.1. Plasmids
Initially, the expression plasmids Hgpsyn [30] and pConBgp140GC/D [31] carrying
codon-optimized sequences for HIV Gag/pol or HIV Env, respectively, were used for DNA
immunizations. Plasmids encoding the codon-optimized sequences of RSV-F or IAV-HA have been
described previously [32]. For the direct comparison, new expression plasmids were generated based
on the pVax vector and each encoded a fusion construct of the soluble ectodomain of the respective viral
surface protein and HIV p24 as an internal control antigen. The ectodomains of HIV-Env, RSV-F, and
IAV-HA were amplified without the transmembrane and intracytoplasmic domain by specific PCRs
and cloned separated by a G4S linker at the N-terminal position of HIV p24 into pV-mDEC-HIVp24 [33].
The resulting plasmids are referred to as gp140-p24, F-p24 and HA-p24 respectively and lead to the
expression of secreted fusion proteins. Since p24 alone is not secreted, an additional control plasmid,
referred to as p24, was used in the immunization which mediates the secretion of a non-fused p24
by a TPA leader signal. Further Env–p24 fusion constructs were generated in which the gp140 was
stepwise shortened by cutting after the respective variable region. All expression cassettes contain a
CMV promotor and an additional HIS6-Tag at the N-terminus for purification purposes. A schematic
overview on the ORFs of the new constructs is shown below in Figure 1.
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analyzed by Western Blot. 
In brief, a SDS-PAGE was performed at a constant voltage of 140 V for 90 min followed by a 
transfer of the proteins on nitrocellulose membrane at 100 V for 1 h. Afterwards, blotted proteins 
were made visible by using antigen-specific antibodies for the respective encoded proteins 
(polyclonal a-F and a-HA antiserum from mice co-vaccinated with F and HA; polyclonal a-gp120, 
Acris, Herford, Germany; monoclonal a-p24, NIH AIDS reagent program) and matched secondary 
antibodies linked to horseradish peroxidase. Incubation with Chemi Glow West substrate solution 
(Protein Simple, San Jose, CA, USA) led to a chemiluminescent reaction which was recorded with a 
luminometer (Hamamatsu Photonics, Hamamatsu, Japan). 
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2.2. Expression Analyses
To confirm antigen expression, cells of the human embryonic kidney cell line 293-T (HEK 293T;
ATCC CRL-3216, LGC Standards, Wesel, Germany) were transfected with the respective plasmids. For
25-cm2 flasks, a formulation of 10 µg of plasmid DNA and 15 µg of polyethylenimine (PEI) in 500 µL
serum-free DMEM (Life Technologies, Carlsbad, CA, USA) was used. Upon transfection, the cells were
incubated in DMEM containing 1% FCS (Life Technologies) in a humid atmosphere with 5% CO2 at
37 ◦C and the supernatants were harvested 48 h post transfection. After clearance by centrifugation
(940× g for 10 min), the cell free supernatants were mixed with SDS sample buffer and analyzed by
Western Blot.
In brief, a SDS-PAGE was performed at a constant voltage of 140 V for 90 min followed by a
transfer of the proteins on nitrocellulose membrane at 100 V for 1 h. Afterwards, blotted proteins were
made visible by using antigen-specific antibodies for the respective encoded proteins (polyclonal a-F
and a-HA antiserum from mice co-vaccinated with F and HA; polyclonal a-gp120, Acris, Herford,
Germany; monoclonal a-p24, NIH AIDS reagent program) and matched secondary antibodies linked
to horseradish peroxidase. Incubation with Chemi Glow West substrate solution (Protein Simple,
San Jose, CA, USA) led to a chemiluminescent reaction which was recorded with a luminometer
(Hamamatsu Photonics, Hamamatsu, Japan).
2.3. Mice and Immunization
All animal experiments performed during this study were approved by an external ethics
committee authorized by the North Rhine-Westphalia Ministry for Environment and Nature Protection,
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Agriculture and Consumer Protection with the project licenses (AZ 84-02.04.2015.A082, approved
at 28.07.2015). Six- to eight-week old BALB/cJRj and C57BL/6J mice were purchased from
Janvier Laboratories (Le Genest-Saint-Isle, France) while Myd88/Trif−/− mice were provided by C.
Kirschning [34]. Card9−/− mice were generated by Jürgen Ruland and backcrossed at the TiHo
Hannover [35]. All mice were housed in individually ventilated cages in accordance to the national
law and institutional guidelines at the animal facility of the Faculty of Medicine, Ruhr-University
Bochum. DNA immunizations were performed as described previously [13]. Briefly, animals were
anesthetized with ketamine/xylazine and received 15 µg of plasmid DNA in 30 µL of PBS in each hind
leg followed by local application of an electric pulse (TriGrid; Ichor Medical, San Diego, CA, USA). A
boost immunization following the same schedule was performed four weeks after the priming.
2.4. Determination of Humoral Immune Responses
Three and six weeks after the prime immunization, serum samples were collected and used to
determine the humoral immune response by antigen-specific antibody-ELISAs. Ninety-six-well plates
were coated with the respective antigen dissolved in 0.1 M bicarbonate buffer (pH 9.6) (RSV-F, Sino
Biological, Beijing, China, 100 ng/well; IAV-HA, inactivated IAV-particles, 106 PFU/well; gp140-his,
own purification, 100 ng/well; Gag-GST, own purification, 150 ng/well) at 4 ◦C overnight. After
washing with PBS-T, the coated plates were blocked with 5% skim milk powder in PBS-T and then
incubated for 1 h at room temperature (RT) with the immune sera in a dilution range from 10−3–10−4
in 2% skim milk powder in PBS-T. Upon this, the plates were washed again and incubated for 1 h at RT
with HRP-conjugated anti-IgG1 or anti-IgG2a antibodies (both BD Biosciences, Heidelberg, Germany)
diluted in skim milk. The amount of bound antibody was measured by a luminescent reaction detected
by a microplate luminometer (Orion, Berthold Detection Systems, Bad Wildbad, Germany). In order to
allow a direct comparison, both detection Abs were verified to yield the same relative light unit values
for a given amount of the respective IgG subclass antibodies.
2.5. Determination of Cellular Immune Response
To determine the cellular immune response, six weeks after the initial immunization the spleens
were collected in 5 mL HBSS (Life Technologies) and single-cell suspensions were prepared using
a 70 µm cell strainer. After red blood cell lysis, splenocytes were resuspended at a cell density
of 107/mL in RPMI 1640 (Life Technologies) supplemented with 10% FCS (Life Technologies), 1%
penicillin/streptomycin (Life Technologies), 10 mM HEPES, 4 mM L-glutamine (Life Technologies), and
50 µM 2-mercaptoethanol. Intracellular cytokine staining was performed as previously described [13].
Briefly, 106 splenocytes/well were seeded in a 96-well U bottom plate and stimulated with 5 µM
of MHC-II restricted peptides (RSV-F: GWYTSVITIELSNIKE; IAV-HA: SFERFEIFPKE; HIV-Env:
GVPVWKEATTTLFCASDAKA; HIV-Gag: PVGEIYKRWIILGLN and SPEVIPMFSALSEGA) in the
presence of monensin (2 µM) and 1 µg/mL of an anti-CD28-antibody (BD Bioscience).
After 6 h incubation, the cell surface was stained with anti-mouse CD4-PerCP-eFluor710 and
Fixable Viability Dye eFluor 750 (both eBioscience, Frankfurt a. M., Germany). The cells were then fixed
with 2% paraformaldehyde and permeabilized using 0.5% saponin. For the detection of intracellular
cytokines, anti-mouse TNF-α PE-Cy7, IFN-γ PE (both eBiosciece), and IL-2 APC (BD Bioscience) were
used. Data were obtained with a FACS Canto II (BD Bioscience) and processed with FlowJo (Tree Star,
Ashland, OR, USA).
For the cytokine-specific ELISA, 5 × 106 cells/per well were seeded in 48-well plates and
stimulated with the above-mentioned MHC II-restricted peptides (5 µg/mL). After two days of
incubation, the culture supernatants were analyzed for the presence of the cytokines IL-4, IL-5, IL-10,
and IL-13 by the cytokine specific Ready-set-go! ELISA (eBioscience) according to the manufacturer’s
instructions. Optical densities were acquired with a Sunrise ELISA reader (Tecan, Crailsheim, Germany)
at 450 nm with 620 nm as reference wavelength.
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For the cytokine-specific ELISA, 5 × 106 cells/per well were seeded in 48-well plates and
stimulated with the above-mentioned MHC II-restricted peptides (5 µg/mL). After two days of
incubation, the culture supernatants were analyzed for the presence of the cytokines IL-4, IL-5, IL-10,
and IL-13 by the cytokine specific Ready-set-go! ELISA (eBioscience) according to the manufacturer’s
instructions. Optical densities were acquired with a Sunrise ELISA reader (Tecan, Crailsheim, Germany)
at 450 nm with 620 nm as reference wavelength.
2.6. Statistical Analysis
Two-tailed Mann-Whitney tests, two-tailed unpaired t tests, one-way ANOVA with Tukey’s
post-test, Kruskal-Walli’s test with Dunn’s post-test signed rank test were performed as indicated in
the figure legends using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA)
3. Results
3.1. Differential Antibody Response to Viral Glycoprotein after DNA Immunization
Previously, we reported that the antibody response to HIV Env in mice differed from the one to
HIV Gag even if the DNA vaccines encoding these two antigens were co-administered at the same
site [13]. Since Gag and Env differ in a number of aspects, including their subcellular localization, we
extended our comparisons by using other viral transmembrane proteins delivered by the same DNA
vaccination protocol. Balb/c mice were immunized via DNA electroporation with plasmids encoding
the HIV antigens, the F protein from RSV, or the HA from IAV. The analyses of the IgG subclass
distribution for the antibody responses to Env, Gag, F, and HA revealed the excessive induction of IgG1
responses only for the Env antigen. Although F and HA were also expressed as membrane-anchored
surface proteins, the antibodies targeting these proteins showed a balanced IgG2a/IgG1 ratio as
observed before for the Gag-specific response (Figure 2). Therefore, we can exclude that expression of
proteins on the surface of cells is sufficient for the induction of IgG1 dominated antibody responses.
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encode for fusion proteins of the soluble extracellular domain of the respective viral surface protein 
and the HIV p24, the capsid protein of HIV (Figure 1). Their application resulted in the expression 
and secretion of F-p24, HA-p24, and gp140-p24 fusion proteins, respectively. In this manner, 
differential budding or shedding from transmembrane proteins are circumvented and all proteins 
can be recognized by the immune systems in the same soluble, monomeric form. Furthermore, we 
included an additional antigen, the HIV p24, to control whether the viral glycoproteins also affect 
the immune response to the fused protein. After DNA immunization with these plasmids, the 
antibody responses to the glycoproteins as well as to p24 were characterized by ELISA. All antigens 
induced strong antibody responses and the overall levels were not substantially different. However, 
Figure 2. Differential humoral immune responses after DNA immunizations. Balb/c mice
were immunized with either a combination of Env- and Gag-encoding plasmids (Hgpsyn and
pConBgp140GC/D), or with RSV-F- or IAV-HA-encoding plasmids. Two weeks after the second
immunization, antigen-specific IgG1 and IgG2a were determined via ELISA for each antigen separately
and IgG2a/IgG1 ratios were calculated. Each Symbol represents an individual animal and geometric
means are indicated by the solid lines. (n = 5–6, ** p < 0.01; Kruskal-Wallis with Dunn’s post-test).
This supports the notion that intrinsic properties of Env lead to the modulation of the antibody
response. For an additional side-by-side comparison, expression plasmids were constructed which
encode for fusion proteins of the soluble extracellular domain of the respective viral surface protein
and the HIV p24, the capsid protein of HIV (Figure 1). Their application resulted in the expression
and secretion of F-p24, HA-p24, and gp140-p24 fusion proteins, respectively. In this manner,
differential budding or shedding from transmembrane proteins are circumvented and all proteins can
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be recognized by the immune systems in the same soluble, monomeric form. Furthermore, we included
an additional antigen, the HIV p24, to control whether the viral glycoproteins also affect the immune
response to the fused protein. After DNA immunization with these plasmids, the antibody responses to
the glycoproteins as well as to p24 were characterized by ELISA. All antigens induced strong antibody
responses and the overall levels were not substantially different. However, the response to RSV-F was
dominated by antibodies of the IgG2a subclass whereas the Env-specific antibodies were again mainly
of the IgG1 subtype (Figure 3A). The IgG2a/IgG1 ratio for the HA-specific antibodies was slightly
below one in this experiment. Notably, the antibody responses to the fused p24 paralleled the IgG
subtype distribution observed for the respective glycoprotein (Figure 3B). Specifically, antibodies to
p24 in animals vaccinated with F-p24 were almost equally distributed to IgG1 and IgG2a whereas
in gp140-p24 treated animals the ratios of IgG2a/IgG1 for p24-specific antibodies were significantly
shifted to IgG1.
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Figure 3. Antibody responses induced by DNA vaccines encoding p24 fusion proteins. Balb/c mice
were immu ized twice with the plasmids F-p24, HA-p24, gp140-p24, and p24, encoding fusions
proteins as depicted in Figure 1. Two weeks after the booster immunization, the antibody levels specific
for the respective surface proteins (A) r for the p24 antigen common to all fusion proteins (B) were
determined by antigen-specific ELISAs (serum dilution 1/10,000). The RLUs for both IgG1 and IgG2a
are depicted as mean values with SEM for the vaccine groups (top) and the ratio of RLUs for IgG2a
to IgG1 were calculated for each mouse individually (bottom). The bars show the geometrical mean
values (n = 6; * p < 0.05, ** p < 0.01, *** p < 0.001, Kruskal-Wallis-test with Dunn’s post-test). (C) Linear
regression analysis (Pearson) between the IgG2a/IgG1-ratios to the surface protein and the fused p24.
Immunization with an additional control plasmid encoding p24 secreted by a TPA leader sequence
also induced a slightly higher IgG1 than IgG2a response. This is in contrast to our former results
with full Gag and might be attributable to the different localization of Gag (intracellularly) and p24
(extracellularly). Given the strong correlation of the IgG2a/IgG1 ratios for F, HA, and gp140 with the
respective ratio to p24 (Figure 3C), however, we conclude that the immune modulatory property of
HIV Env also influenced the response to the fused p24.
3.2. HIV Env Modulates T-Helper Cell Response
The antigen-specific CD4+ T-cell responses were analyzed by intracellular cytokine staining and
cytokine LISA to explore wheth r the diff rential antibody responses might be a consequence of
differences in the glycoprotein specific T helper cell responses. All vaccinated animals mounted
specific T-cell responses to the respective glycoprotein as well as to the fused p24 as indicated by the
capacity to produce typical TH1 cytokines, namely IFN-γ and TNF-α, after re-stimulation with cognate
peptides (Figure 4A). Surprisingly, the percentages of cytokine-producing cells were even higher
after stimulation with the Env peptide than after F or HA peptide stimulation. However, only the
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p24-specific response allows a direct comparison between the groups and this revealed no significant
differences in TH1 responses induced by F-p24, HA-p24 or gp140-p24.Viruses 2019, 11, x 7 of 16 
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Figure 4. Cellular responses induced by DNA vaccines encoding p24 fusion proteins. Balb/c mice
were immunized twice with DNA vaccines coding for the p24 fusion-proteins and antigen-specific
CD4+ T-cell responses were analyzed two weeks after the booster immunization. Intracellular cytokine
staining was used for the detection of the typical TH1 cytokines. The percentages of IFN-γ, TNF-α,
and IL-2 producing CD4+ T-cells as well as polyfunctional triple positive cells are depicted in (A). The
peptide used for the in vitro re-stimulation is shown at the x-axis of each graph. The analysis of TH2
cytokines was performed by cytokine specific ELISAs (B). In each graph, the bars represent the mean
values with SEM of 4–6 mice (# p < 0.05 vs. naïve, ## p < 0.01 vs. naïve, ### p < 0.001 vs. naïve; * p <
0.05, ** p < 0.01, *** p < 0.001; one-way ANOVA with Tukey’s post-test).
Since TH2 cytokines are more difficult to assess in the ICS, the levels of IL-4, IL-5, IL-10 and
IL-13 were determined by ELISA in the supernatant after re-stimulation for 48 h (Figure 4B). High
amounts of IL-5 and IL-13 were released by splenocytes from gp140-p24 immunized animals after
stimulation with either Env or p24 peptides indicating the presence of Env- and p24-specific TH2
cells. In contrast, IL-4 and IL-10 were produced at comparable levels in all groups. Furthermore,
cells from F-p24 treated animals produced significantly lower levels of IL-5 and IL-13 than the one
from the gp140-p24 group. Taken together with the dominant IgG1 response, these results suggest
that an intrinsic property of HIV Env leads to the induction of an unusual TH2 response possibly by
modulating antigen-presenting cells.
3.3. CLR- but Not TLR-Mediated Signaling Might Be Involved in Env-Mediated Immune Modulation
To address the question whether Env could modulate APCs directly by binding to and/or
activation of different PRRs than the other two viral glycoproteins, we employed Myd88/Trif−/− and
Card9−/− mice lacking TL /IL-1 receptor and CLR functions, respectively. Since these knock-out strai s
were on the genetic C57Bl/6 background, we first demo strated that the IgG1 bias for t e Env-specific
antibodies was not specific for Balb/c mice (Figure 5). Again, balanced IgG2c/IgG1 responses were
measur d for RSV-F whereas gp140-p24 mainly induced Env-sp cific IgG1 antibodi s resultin in
significantly different IgG2c/IgG1 ratios for these two grou s. I portantly, the p24 specific response
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was modulated as well (Figure 5). The F-p24 and gp140-p24 immunogens were selected for a direct
comparison, since these two immunogens showed the largest difference in wild type mice. Of note,
similar levels of the TH2 cytokines IL-4, IL-5 and IL-13 were detected in supernatants of env-stimulated
splenocytes ruling out possible differences in the cytokine levels due to the genetic background.
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Figure 5. Biased immune responses to HIV Env in C57Bl6 mice. C57Bl/6J mice were immunized with
the plasmids F-p24, HA-p24 and gp140-p24. The levels of IgG1 and IgG2c specific for the respective
surface antigen (left) or the internal p24 (right) were determined by ELISA (top) and the IgG2c/IgG1
ratios were calculated for each individual animal represented by the symbols (bottom). The bars
represent the mean values with SEM (top), whereas the lines represent the geometrical mean for each
vaccine group (bottom). (n = 6; * p < 0.05, ** p < 0.01, ns = not significant, Kruskal-Wallis-test with
Dunn’s post-test).
In Myd88/Trif−/− mice the humoral response to both antigens, F-p24 and gp140-p24, was not
altered as compared to wild type controls (Figure 6A). Particularly, the F-specific response involved
comparable levels of IgG1 and IgG2c whereas only low amounts of Env-specific IgG2c antibodies
were detectable in both, the wild type as well as in the Myd88/Trif−/− animals. In contrast, a
significant reduction of IgG1 antibodies was detected in Card9−/− mice immunized with gp140-p24
although IgG2c responses were unchanged in comparison to immunized wild type animals (Figure 6B).
CARD9 is an essential adaptor molecule for several CLRs including Dectin-1, Dectin-2, Mincle, or
Clec5a. Importantly, the reduction in IgG1 levels as compared to WT animals was not observed after
vaccination with F-p24 (Figure 6B). These findings suggest that different glycosylation patterns of
RSV-F and HIV Env and subsequent engagement of certain, not yet identified, CLRs may play an
important role for the differential immune response.
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Figure 6. Impact of TLR- or CLR-signaling on the antibody response. Myd88/Trif−/− (A) or Card9−/−
(B) mice were immunized with either F-p24 or gp140-p24 as described above and compared to WT
C57Bl/6J mice. The levels of IgG1- and IgG2c specific for RSV-F or HIV-Env were determined by ELISA
at a serum dilution of 1:1000 for both knock-out strains. Again, the IgG2c/IgG1 ratios were calculated
for the individual animals represented by the symbols (n = 2–3 for Myd88/Trif−/−; n = 6–9 for Card9−/−).
The bars represent the mean values with SEM (top), whereas the lines represent the geometrical mean
for each vaccine group (bottom) (* p < 0.05, ns = not significant, Student’s t-test).
3.4. Glycosylations in the C2V3 Region Determine the IgG1 Bias
Next, we addressed the question whether certain domains of HIV Env are involved in the
i mune modulation by generating plas ids e i i roteins with partial deletions of the
xtracellu ar domain of gp140. Therefore, progressive C-terminal deletions of gp120 were fused to the
p24 antige as depicted in Figure 1. Immunizatio of Balb/c mice with the respectiv DNA constructs
revealed the typical excess of Env-specific IgG1 antibodies in all groups except the on which r ceived
the shortest construct, namely V1V2-p24 (Figure 7). This gro p mounted IgG2a levels comparable
to the other groups, but weake IgG1 responses indicating a specific in rease of Env-specific IgG1 by
inclusion of the C2V3 domai s. Interestingly, the ntibody ponse to the V3-p24 protein was almost
as strong as to the full-length gp140-p24 construct despite having fewer potential epitopes available
due to its smaller size. To exclude a gener l impairment in the immunogenicity of V1V2-p24, we
agai analyzed the T-cell response gainst the immunodominant Env peptide which is present i all
constructs. The ICS revealed no significant differences in the perce tages of cytokine-producing CD4+
T-cells (TH1) in all vaccinated groups, although the respo ses in V5-p24 and gp140-p24 tended o be
lightly higher (Figure 8A). Im ortantly, the CD4+ T-cell response in the group V1V2-p24 was similar
to the remaining groups proving the immunogenicity of this construct.
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Figure 7. Humoral immune responses after vaccination with truncated variants of Env. Balb/c mice
were vaccinated twice with the plasmids encoding the truncated Env-variants V1V2, V3, V4, V5, and
the parental gp140 construct, depicted in Figure 1. Two weeks after the booster immunization, the
Env-specific antibody responses were determined by ELISA. The upper part shows the levels of IgG1-
and IgG2a-antibody response in each group (n = 6) as mean values with SEM. The lower part shows
the ratio of IgG2a to IgG1 calculated individually for each animal with bars indicating the geometrical
mean values. Each symbol represents an individual animal.
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Figure 8. Cellular immune responses to the truncated variants of Env. Balb/c mice were vaccinated
twice with the plasmids encoding the truncated Env-variants V1V2, V3, V4, V5, and the parental gp140
construct. Env-specific CD4+ T-cell responses were analyzed two weeks after the immunization.
Intracellular cytokine staining was used for the detection of the typical TH1 cytokines and the
percentages of IFN-γ, TNF-α and IL-2 producing CD4+ T-cells as well as polyfunctional triple positive
cells are depicted in (A). In contrast, the analysis of TH2 cytokines was performed by a cytokine specific
ELISA (B). In each graph, the bars represent the mean values with SEM of 4–6 mice (* p < 0.05, one-way
ANOVA with Tukey’s post-test).
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However, consistent with the reduced amount of IgG1 antibody response, Env-specific TH2
responses were nearly absent in this group as indicated by low amounts of IL-4, IL-5, IL-10, and
IL-13. These cytokines became readily detectable when the C2V3 domains were present in the
construct (Figure 8B). In accordance with the ICS data, the T-cell response to Env seemed to reach
the maximum in the case of the V5-p24 construct. Since CLR signaling is involved in immune
modulation, the glycosylation pattern of the C2V3 region might play an important role for the shift
towards a TH2 response and subsequent IgG1 production. Therefore, we mutated all potential
N-glycosylation sites to codons for glutamine in C2V3 resulting in the new construct, V3NQ-p24. The
mutations led to the expected size reduction due to the missing glycosylation as revealed by Western
Blot analyses of transfected 293 T-cells. However, both proteins were efficiently secreted into the
supernatant and successfully fused to p24 (Figure 9A). Immunization with V3NQ-p24 induced IgG2a
responses comparable to the fully glycosylated V3-p24, but the IgG1 response was significantly reduced
(Figure 9B). Interestingly, the formerly imprinted bias in the antibody response to the fused p24 was
also reverted and V3NQ-p24 immunized animals show a balanced IgG2a/IgG1 ratio (Figure 9C).
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analyses of the supernatants with an p24-specific antibody. (V3 = glycosylated, V3NQ = not 
glycosylated, pGL = transfection control, untrans. = untransfected). Balb/c mice were immunized as 
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IgG2a-antibodies as mean values with SEM for six animals each (* p < 0.05, ns = not significant, 
Student’s t-test). The lower part depicts the ratio of IgG2a to IgG1 for each animal with bars 
indicating the geometrical mean values (* p < 0.05, ns = not significant, Mann-Whitney-test). 
This also confirmed the overall immunogenicity of the non-glycosylated protein. Finally, the 
TH2 responses were again addressed by cytokine ELISA. Here, the effect of the deglycosylation was 
even more pronounced with significantly higher levels of IL-4, IL-5 and IL-13 after Env 
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Figure 9. Impact of the glycosylation of the C2V3 region on the humoral immune response. (A) To
delete all potential N-glycosylation sites from the C2V3 region, the Asn-coding triplets (indicated by
arrows) in the construct V3-p24 were mutated to Gln-coding ones. 293T cells were transfected with the
new construct, V3NQ, and deglycosylation of the Env variant was confirmed by Western Blot analyses
of the supernatants with an p24-specific antibody. (V3 = glycosylated, V3NQ = not glycosylated, pGL
= transfection control, untrans. = untransfected). Balb/c mice were immunized as described above
with either V3-p24 or V3NQ-p24 and the antibody responses to Env (B) and p24 (C) were analyzed
two weeks post boost immunization. The upper part shows the level of IgG1- and IgG2a-antibodies
as mean values with SEM for six animals each (* p < 0.05, ns = not significant, Student’s t-test). The
lower part depicts the ratio of IgG2a to IgG1 for each animal with bars indicating the geometrical mean
values (* p < 0.05, ns = not significant, Mann-Whitney-test).
This also confirmed the overall immunogenicity of the non-glycosylated protein. Finally, the
TH2 responses were again addressed by cytokine ELISA. Here, the effect of the deglycosylation was
even more pronounced with significantly higher levels of IL-4, IL-5 and IL-13 after Env restimulation
in animals immunized with the fully glycosylated V3-p24. In contrast, splenocytes from V3NQ-p24
treated animals hardly produced IL-5 and IL-13 after stimulation with either Env or p24 supporting
the hypothesis that the glycosylation pattern of Env directly impacts T-cell polarization (Figure 10).
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Figure 10. Impact of the glycosylation of the C2V3 region on TH2 responses. Balb/c mice were
immunized twice in a 4-week interval with either V3-p24 or V3NQ-p24. Two weeks after the booster
immunization, the cellular immune response to Env and p24 was analyzed via cytokine-specific ELISA.
Depicted are the levels of the IL-4 (A), IL-5 (B), IL-10 (C) and IL-13 (D) as mean values with SEM (n =
4–6, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant, One-Way ANOVA with Tukey’s post-test).
4. Discussion
Several studies reported a predominant mouse IgG1 antibody response to the HIV Env protein
after infection or vaccination which coincided with a strong induction of Env-specific TH2 T-helper
cell responses [13–16]. Although substantial differences in the functional profile of human IgG1
and th murine count rpart exist, there are als several reports on dominating IgG1 responses to
Env in HIV–i fected individuals or gp120 vaccine recipients whi h do not seem to orrelate with
protection [3,36,37].
Since the bias in the antibody response t the unfavorable IgG1 subclass was obs rved for different
vaccination approaches, including immunization using protein, DNA, or viral vector vaccines, an
inherent property of the Env molecule seems to be responsible for this kind of immune modulation.
In our previous study, t co-delivery of plasmids encoding either HIV Env or HIV Gag resulted
in a balanced IgG1/IgG2a response towards HIV Gag, but in a TH2-dominated IgG1 respons t
HIV E v [13]. Sinc both antigens w re deliver d in th same muscle and T-cell priming most likely
occurred in the same draining lymph node, this observation argues against a general Env induced
cytokine milieu f voring TH2 responses. Supporting the idea of an inhere t property f HIV Env, in
this study, a DNA vaccine encoding HIV Env covalently link to HIV p24 indu ed a biased antibody
response not only to E v, but also to p24. This again was in sharp contrast to the other DNA vaccine
encoding the p24 fused to RSV-F, which induced balanced IgG1/IgG2a responses to both antigens.
By using the soluble fusion proteins, w also confirm that the biased antibody response is not a
conseque ce f the membra e-anchored trimeric form of HIV Env. Since this bias was acc mp nied by
the alteration of p24-specific CD4+ T-cell resp nses, a plausible explanatio for the modulatory effect
of HIV Env is the differential binding and/or signaling via PRRs on antigen-presenting cells. Although
TLR-mediated immun activation was reported for HIV Env (TLR2/4) [38] as well as for RSV-F
(TLR4) [39], immunization of Myd88/Trif−/− mice did not reveal any impact on the vaccine-induced
immune resp nse excluding a TLR employment by Env. Although the small group sizes in this
experiment might limit the significance, there were no cha ges in the over ll antibody levels or the
subtype distribution. In contrast, Card9−/− mice lacki g an essential adaptor protein for specific CLR
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signaling pathways displayed significantly reduced levels of Env-specific IgG1 antibodies, whereas
the IgG2 response was not changed. Given the similarity of the IgG1 responses to RSV-F in wild type
and Card9−/− mice, our data exclude a general defect in the IgG1 antibody repertoire due to a lack of
CARD9 function. Consequently, the extensive glycosylation of HIV Env might lead to the recognition
by specific, not yet identified CLRs, which can directly impact APC maturation and subsequently
T-cell differentiation. Potential candidate CLRs known for direct signaling via CARD9 are Dectin-1,
Dectin-2 and Mincle which bind different glycan PAMPs (e.g., on mycobacterium tuberculosis or
specific fungi) to support specifically TH1, TH2 or TH17 responses [22–24,40]. Since the bias in the
antibody response was not completely absent from Card9−/− mice, additional CLRs/PRRs might
be involved in a cooperative immune modulation. Two additional receptors reported to interact
with Env are the mannose receptor [28] and SIGLEC-1 on macrophages [41,42], the former of which
mediates release of IL-10 [28] while the latter generally dampens innate and inflammatory immune
activities [43,44].
Using plasmids encoding successively shortened Env variants, we were able to demonstrate
that the presence of the C2V3 region led to the induction of Env-specific TH2 T-cell responses which
coincided with a dominant IgG1 antibody response. Since the T-cells from all animals were stimulated
with a single peptide located in the C1 region of HIV Env, differences in the T cell responses observed
can not be due to differences in the epitope recognition. Thus, the results support the idea of a
differential programming of the T-cells by APCs. Interestingly, the percentages of T-cells producing
typical TH1 cytokines and the levels of IgG2a antibodies remained constant independent of the length
of the protein. Since the results from the Card9−/− mice supported the hypothesis of a crucial role
for the glycan structure of HIV Env, we removed all eight potential N-glycosylation sites from the
C2V3 region by N-to-Q mutation to revert the immune modulatory effect of this domain. Indeed,
vaccination with the deglycosylated construct induced a balanced IgG2a/IgG1 antibody response
and a significant reduction of TH2 cytokines compared to the fully glycosylated V3-p24 construct.
Interestingly, nearly all glycan structures in the C2 region belong to the oligomannose class, whereas
more complex glycans were reported to be found in V1/V2 [45]. The highly repetitive mannose
structures are known ligands for a series of CLR, including the MR, DC-SIGN, Dectin-2 or Mincle.
Furthermore, it has been reported that the amount of oligomannose residues on viral glycoproteins
can have a direct impact on DC maturation. Recombinant HA produced in CHO cells in the presence
of kifunensine had less complex glycan structures and higher numbers of high-mannose glycans
which results in stronger upregulation of CD86 and CD40 in murine DC [46]. In accordance with the
observation in Card9−/− mice, binding of HIV Env via the mannose structures to receptors like Mincle
or Dectin-2 might be also a possible explanation for differential signaling in APCs. Although all our
experiments revealed a strong association of the TH2 T-cell response with the IgG1 predominance,
we formally can not rule out partially T-cell independent effects on the B-cell response mediated by
the glycosylation structure of HIV Env. It has been reported that HIV gp120 can bind and activate
B-cells via DC-Sign and/or MR which finally result in class-switch recombination in B-cell when acting
together with additional stimuli, like BAFF [47,48]. Since BAFF expression is induced by IL-4 and IL-10,
it is also possible that the T-cell independent reaction is supported by the cytokine milieu. Although it
is worthy to speculate that both T-cell dependent and independent mechanisms might contribute both
to the biased antibody response, so far the T-cell independent activation of B-cells has not been yet
linked to a certain subclass of IgGs.
Finally, with the results of the immunization study in the knock-out mice and the antibody
responses to the truncated and deglycosylated Env variants we have two independent lines of
evidence that the glycosylation of HIV Env is directly responsible for the reported immune modulation.
Although we have not yet identified the CLRs recognizing HIV Env, we can speculate that either a
particular subpopulation of APCs is targeted by the specific CLR/glycan interaction leading to the
induction of specific TH2-polarized T-cells or the signaling within the APC is directly influenced
by the binding, as it is reported for Mincle or Dectin-2, for example. It will be of great interest to
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identify the potential receptor and analyze in detail its role for this specific immune modulation,
since inducing an unfavorable TH-2 dominated immune response may actually constitute an immune
evasion mechanism. A deeper understanding of the influence of glycan structures on antigen-specific
T-cell responses will be also of great value for the development of new vaccines targeting viral
surface proteins.
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